These biotech stocks jumped by 35% or more over the last few days. But can their momentum continue?
News & Analysis: Bioverativ
On a record day for the market, Halliburton reported a strong quarter and Sanofi is buying Bioverativ in a big biotech deal.
Sanofi made its first major acquisition in nearly seven years by buying the hemophilia specialist Bioverativ.
Biogen spinoff Bioverativ is on a roll that doesn't seem likely to slow down anytime soon.
Industry Focus takes on Biogen Inc.'s fourth-quarter earnings and the company's decision to spin-off its hemophilia drugs as Bioverativ.
Competitors make headway against Teva Pharmaceutical's top seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.